


REMARKS

Applicants hereby elect, without traverse, the invention of Group I, Claims 1 – 7, for further prosecution in the application.

Applicants further elect as the species, the compound of Example 2 on page 68 of the application, identified as (2S)-2-(3(S)-Acetyl-amino-3-( (S)-sec-butyl)-2-oxo-pyrrolidin-1-yl)-N-[(1S,2R)-1-(3,5-difluorobenxyl)-2-hydroxy-3-(3-methoxy-benzylamino)-propyl]-4-phenyl-butamide, and represented structurally below:



It is believed that all of the elected claims 1-7 read on this embodiment.

The application is believed to be in condition for allowance, and prompt, favorable action thereon is earnestly solicited. Should Examiner Royds feel that any other point requires consideration, then she is cordially invited to contact the undersigned.

Respectfully submitted,



John F. Levis  
Attorney for Applicant  
Reg. No. 34,210  
Phone: 203-677-3782  
Date: July 2, 2008

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000